Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in... Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Infection Springer Journals

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Infection , Volume 46 (3) – Feb 19, 2018

Loading next page...
 
/lp/springer_journal/ceftolozane-tazobactam-therapy-for-multidrug-resistant-pseudomonas-F0OtIVU9Kk

References (19)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Infectious Diseases; General Practice / Family Medicine; Internal Medicine
ISSN
0300-8126
eISSN
1439-0973
DOI
10.1007/s15010-018-1125-5
pmid
29460229
Publisher site
See Article on Publisher Site

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

Journal

InfectionSpringer Journals

Published: Feb 19, 2018

There are no references for this article.